Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Pakman2000 who wrote (886)	7/9/1998 3:18:00 PM
From: ahhaha	Read Replies (1) \| Respond to of 1510

I knew all about the AGPH news weeks ago. It was public knowledge. The public was trying to position themselves for the Geneva Conference in order to make a trading killing. They got bagged. I believe that is what AHM was doing. Nothing new about IMNR has been released except the AGPH and SGP news for some time. These are constructive develops but only because they lend credence to the validity of the company's biotechnology. The most bullish aspect of this stock is that you can't trade it. It truly reflects the intrinsic development of fundamentals, the slow grinding process of valid procedure. Also, Wall Street and the pharmacological sector sneer at the top down approach that is the hallmark of IMNR. They're all wrong because biophysics is too complicated from the bottoms up direction. If there is any headway possible in biotechnology it has to be organic, organism based rather than chemistry based. Once IMNR has more success, they will pioneer a major shift in biotechnology emphasis towards finding ways to support or enhance what our bodies do so well now.